SEECABG: Efficacy of External CounterPulsation for Postoperative Coronary Artery Bypass Grafting Patients

Sponsor
Mengya Liang (Other)
Overall Status
Unknown status
CT.gov ID
NCT03235323
Collaborator
(none)
120
1
2
47
2.6

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the effect of External CounterPulsation on postoperative heart function and vein graft failure rates of coronary artery bypass grafting patients.

Condition or Disease Intervention/Treatment Phase
  • Device: External Counterpulsation
N/A

Detailed Description

Coronary artery disease (CAD) is prevalent worldwide and the leading cause of mortality of citizens. Coronary Artery Bypass Grafting (CABG)is one of the major revascularization procedures for multi-vessel disease nowadays. However vein graft failures (VGF) are known to occur frequently following CABG surgery . It is estimated that VGF developed in 25% patients in half a year postoperatively, and up to 50% vein grafts would result in occlusion in ten years postoperatively. Surgical success depends on the continued patency of grafts, and VGF has been associated with worse outcomes in CABG patients. Thus prevention of VGF following CABG is an active area of scientific inquiry. External counter pulsation (ECP) is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.ECP has been elucidated that it may release angina symptoms and improve the prognosis of CAD, however, it remained unknown that weather EECP can reduce VGF rates following CABG surgery. The aim of this study is to evaluate the effect of ECP on heart function of CABG patients and VGF rates.

To address this investigation, patients underwent CABG with at least one vein graft are enrolled and randomize them into control or ECP group, the ECP intervention will be carried out with a standard protocol which involves 35 one-hour sessions (5 days a week) for continuous 7 weeks, and the follow-up will last for 2 years. The primary endpoints are the 2-year major composite cardiovascular events (MACEs,) and 2-year vein graft patency rate determined by coronary CT angiography, secondary endpoints include scoring of angina pectoris, heart function by echocardiography, biomarkers of arteriosclerosis and endothelial function.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Study of Efficacy of External CounterPulsation on Reducing the Prevalence of Vein Graft Failure and Improving Cardiac Function for Postoperative Coronary Artery Bypass Grafting Patients
Actual Study Start Date :
Sep 5, 2017
Anticipated Primary Completion Date :
Aug 7, 2020
Anticipated Study Completion Date :
Aug 7, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: ECP group

Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.

Device: External Counterpulsation
ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.

No Intervention: Control group

Patients of Control group received routine medicine treatment postoperatively

Outcome Measures

Primary Outcome Measures

  1. 2-year vein graft patency rate [Two years postoperatively]

    2-year vein graft patency rate determined by coronary CT angiography

  2. 2-year major composite cardiovascular events (MACEs) [Two years postoperatively]

    2-year major composite cardiovascular events,including STEMI/NSTEMI,readmission of heart attack, renal dialysis and acute heart failure

Secondary Outcome Measures

  1. Canadian Cardiovascular Society (CCS) scoring [One and two years postoperatively]

  2. left ventricular end-systolic volume index (LVESVI) and Ejection Fraction [One and two years postoperatively]

    left ventricular end-systolic volume index (LVESVI) and Ejection Fraction by echocardiography

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients underwent coronary artery bypass grafting surgery
Exclusion Criteria:
  • Cerebral hemorrhage within six months;

  • Obvious aortic insufficiency;

  • Aortic aneurysm;

  • Aortic dissection;

  • Coronary fistula or severe coronary aneurysm;

  • Symptomatic Congestive heart failure

  • New York Heart Association(NYHA)heart function class IV

  • Valvular heart disease;

  • Congenital heart diseases;

  • Cardiomyopathies

  • Uncontrolled hypertension, defined as SBP≥180mmHg or DBP≥110mmHg;

  • Lower limb infection;

  • Deep venous thrombosis;

  • Progressive malignancies

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of cardiac surgery, The first affiliated hospital of Sun Yat-sen university Guangzhou Guangdong China 510080

Sponsors and Collaborators

  • Mengya Liang

Investigators

  • Study Director: Zhongkai Wu, Department of Cardiovascular Medcine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mengya Liang, Professor, First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT03235323
Other Study ID Numbers:
  • LS2017-144
First Posted:
Aug 1, 2017
Last Update Posted:
Sep 7, 2017
Last Verified:
Sep 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mengya Liang, Professor, First Affiliated Hospital, Sun Yat-Sen University

Study Results

No Results Posted as of Sep 7, 2017